THE USE OF CYSTINE OR CYSTEINE FOR THE PREVENTION AND TREATMENT OF OXIDATIVE STRESS CAUSED BY HAEMODIALYSIS AND OF ACUTE OR CHRONIC KIDNEY DISEASES

UTILISATION DE CYSTINE OU DE CYSTEINE DANS LA PREVENTION ET LE TRAITEMENT DU STRESS OXYDATIF CAUSE PAR L'HEMODIALYSE ET DES NEPHROPATHIES CHRONIQUES OU AIGUES

English Abstract

The invention discloses the use of cystine and/or cysteine for the preparation
of oral medicinal products for the prevention and treatment of oxidative
stress resulting from haemodialysis treatment in patients suffering from
chronic kidney failure as well as for the treatment and prevention of acute or
chronic kidney diseases and of End-Stage Renal-Disease.

French Abstract

L'invention concerne l'utilisation de cystine et/ou de cystéine dans la préparation de produits pharmaceutiques oraux utilisés dans la prévention et le traitement du stress oxydatif résultant d'un traitement par hémodialyse de patients atteints d'insuffisance rénale chronique, et dans le traitement et la prévention des néphropathies chroniques ou aiguës et de l'insuffisance rénale terminale.

Claims

6



CLAIMS


1. Use of cystine and/or cysteine to prepare oral medicinal products for
the prevention and treatment of oxidative stress resulting from haemodialysis
treatment in patients suffering from chronic kidney disease or End-Stage
Renal Disease.


2. Use as claimed in claim 1, wherein the cystine and/or cysteine is in a
form for administration in unit doses ranging from 200 to 1000 mg.


3. Use as claimed in claim 1 or 2, wherein the cystine and/or cysteine is
in a form for administration before and/or after haemodialysis treatment.


4. A pharmaceutical composition in a form for oral administration for the
prevention and treatment of oxidative stress resulting from haemodialysis
treatment in patients suffering from chronic kidney disease, containing
cysteine or cystine as the active constituent and a pharmaceutically
acceptable
carrier or diluent.


5. Use of from 200 to 1000 mg of cystine and/or cysteine orally before
and/or after the haemodyalisis treatment for the prevention and treatment of
oxidative stress resulting from haemodialysis in patients suffering from
chronic kidney disease.


6. Use of from 200 to 1000 mg of cystine and/or cysteine in a form for
oral administration for the prevention and treatment of patients suffering
from
End-Stage Renal Disease.

Description

CA 02551043 2012-01-27
1

THE USE OF CYSTINE OR CYSTEINE FOR THE PREVENTION AND
TREATMENT OF OXIDATIVE STRESS CAUSED BY
HAEMODIALYSIS AND OF ACUTE OR CHRONIC KIDNEY
DISEASES

This invention relates to the use of cysteine and its disulphide oxidised
form (cystine) to prepare oral medicinal products for the prevention and
treatment of oxidative stress resulting from haemodialysis treatment in
patients suffering from chronic kidney failure.

The invention also relates to the use of cysteine or cystine for the
preparation of a medicament for the treatment and prevention of acute or
chronic kidney diseases.

BACKGROUND OF THE INVENTION

Oxidative stress is defined as an imbalance between the physiological
systems of antioxidant protection and increased production of oxygen or
nitrogen radicals by the cells of the immune system. The result can be damage
to the molecular structure of proteins, sugars and lipids together with damage
to the cell functions, which also prejudices the functions of the body's vital
organs. Oxidative stress has been observed to be particularly evident in

patients suffering from kidney failure and undergoing haemodialysis. This
phenomenon is attributed to bioincompatibility between the patient's
circulating blood cells and the dialysis membranes, together with other
factors
such as a chronic uraemic state. This bioincompatibility leads to excessive
production of Reactive Oxygen Species (ROS) by the immune system, and at

the same time a reduction in the antioxidant capacity of the body due to
losses
of antioxidant molecules such as glutathione (GSH), vitamin A, vitamin C and
vitamin E through the filters of the dialysis membranes.

One of the consequences of this abnormal immune response is a


CA 02551043 2006-06-16
WO 2005/058305 PCT/EP2004/014359
2

condition of oxidative stress, which leads to greater susceptibility to
infection
due to the defective immune response, amyloidosis and accelerated
atherosclerosis due to continual activation of the immunocompetent cells.
This triggers an inflammatory response, with consequent continual release of

cytokines and lysosomal proteolytic enzymes, and stimulation of free radical
production; in practice the oxidative stress becomes a self-replicating
process,
and generates a condition of chronic inflammation.

The main consequence of oxidative stress is cardiovascular
complications, which are the main cause of death in patients suffering from
chronic kidney failure. At local level these complications are manifested by

alterations of the endothelium, accumulation of lipids, formation of clots and
occlusion of the lumen.

At systemic level, chronic oxidative stress stimulates acute-phase
protein synthesis by the liver at the expense of synthesis of other proteins,
such as albumin and transferrin: the result is malnutrition, which is

exacerbated by catabolic breakdown of muscle proteins and reduced appetite.
The chronic renal failure (CRF) is a progressive disease of kidney;
when the kidney has lost all its ability of clear the blood, the patients
cannot
survive and have to be submitted to the dialysis procedure. Such a last
condition is defined End-Stage Renal-Disease (ESRD).

Examples of the treatment of oxidative stress by administering products
with antioxidant activity are reported below. The product most often used for
the prevention and treatment of oxidative stress at present is N-
acetylcysteine
(see, for example, Kidney Int., Vol 64 (2003), pp. 82-91; Current Med. Chem.,

2003, 10, pp. 1241-53). In particular, WO 01/02004 describes the use of
N-acetylcysteine by intravenous injection before and/or during haemodialysis
treatment.

According to Nakanishi et al., Kidney Int. 2003 Mar; 63(3): 1137-40,


CA 02551043 2006-06-16
WO 2005/058305 PCT/EP2004/014359
3

the plasma concentration of cysteine and homocysteine increases in patients
with chronic kidney failure who undergo dialysis. It consequently does not
seem logical to further increase the cysteine concentration in these patients.

Santangelo F., Current Med. Chem., 2003, 10, 2599-2610, has recently
reviewed the therapeutic uses of cysteine pro-drugs such as N-acetylcysteine
and its esters, thiazolidines, y-glutamylcysteine and glutathione esters,
particularly discussing the importance of intracellular GSH concentration. The
oral administration of cysteine or cystine rather than derivatives thereof has
been however neither disclosed nor suggested by this review.

DESCRIPTION OF THE INVENTION

The present invention involves the administration of cystine and/or
cysteine for the prevention and treatment of oxidative stress resulting from
haemodialysis treatment in patients suffering from chronic kidney failure.

According to a further embodiment, the invention also concerns the use
of cystine and/or cysteine for the preparation of a medicament to be
administered by the oral route for the treatment and prevention of chronic or
acute kidney diseases as well as for the treatment and prevention of End-Stage
renal Disease (ESRD).

The use of cysteine is preferred, but other substances known to have
antioxidant properties, such as taurine, lipoic acid, and vitamins A, C and E,
could also be added.

This invention therefore relates to oral compositions containing cystine
and/or cysteine for the prevention and treatment of oxidative stress resulting
from haemodialysis treatment in patients suffering from chronic kidney

failure or for the treatment and prevention of acute or chronic kidney
diseases
or for the treatment and prevention of End-Stage renal Disease (ESRD).

These compositions will be prepared according to conventional
methods well known in pharmaceutical technology, such as those described in


CA 02551043 2006-06-16
WO 2005/058305 PCT/EP2004/014359
4

"Remington's Pharmaceutical Handbook", Mack Publishing Co., N.Y., USA.
This invention involves the oral administration of an effective quantity
of cystine and/or cysteine before and/or after haemodialysis treatment in
patients suffering from kidney failure. This quantity will depend on various

factors, such as the severity of the condition and the patient's weight.
However, a unit dose will generally contain 200 to 1000 mg of cystine and/or
cysteine. The compositions according to the invention will normally be
administered before and/or after the haemodialysis treatment. These
compositions are preferably administered in the form of compositions with an
oral unit dose.

For the treatment and prevention of acute or chronic kidney diseases or
for the treatment and prevention of End-Stage renal Disease (ESRD), the
effective dose of cysteine or cystine ranges from 100 to 1000 mg, from 1 to 4
times a day.

According to a further aspect of the invention, the cystine or cysteine
can be associated with non-toxic oral antioxidants, in particular vitamins A,
C
and E, lycopene, lipoic acid, ascorbic acid and taurine. Vitamin E and taurine
are preferred.

According to the invention, the compositions may be in the form of
tablets, capsules, oral preparations, powders, granules, lozenges,
reconstitutable powders, syrups, solutions or suspensions. The solid
compositions may contain conventional excipients, for example binders such
as cellulose, mannitol and lactose; diluents, such as calcium carbonate,
calcium phosphate and lactose; compression agents; lubricants such as

magnesium stearate; disintegrants such as starch, polyvinylpyrrolidone and
starch derivatives; colorants; flavouring agents and the like.

The liquid compositions may contain conventional excipients, for
example suspending agents such as sorbitol, methylcellulose,


CA 02551043 2006-06-16
WO 2005/058305 PCT/EP2004/014359

hydroxyethylcellulose and carboxymethylcellulose; preservatives, for
example methyl or propyl p-hydroxybenzoate or sorbic acid, and conventional
flavouring agents or colorants if desired.

The oral administration of cystine and/or cysteine offers considerable
5 advantages in terms of cost, ease and safety of administration compared with
the use of intravenous and/or infusion formulations of N-acetylcysteine,
which require skilled personnel for administration before dialysis treatment,
and also involve the risk of contamination during dialysis.